Sareena Singh1, Megan Guetzko2, Kimberly Resnick3. 1. Division of Gynecologic Oncology, University Hospitals Case Medical Center, Cleveland, OH, United States. Electronic address: ssingh3@metrohealth.org. 2. Department of OB/GYN, University Hospitals Case Medical Center, Cleveland, OH, United States. 3. Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, OH, United States.
Abstract
OBJECTIVE: The objective of this study was to identify preoperative characteristics of patients that experience a delay in initiation of adjuvant chemotherapy after primary debulking surgery for ovarian cancer. MATERIALS/ METHODS: We performed a retrospective review of patients with Stage II to IV high-grade epithelial ovarian, tubal, and peritoneal carcinoma who underwent primary debulking surgery followed by adjuvant chemotherapy from 2005 to 2013. Patients were divided into 2 groups: Control (those who received their first cycle of chemotherapy within 6weeks of debulking surgery) vs. chemotherapy delay (those who received their first cycle of chemotherapy at an interval >6weeks from primary debulking surgery). Relevant clinical variables and survival outcomes were compared between the 2 groups using standard statistical methods. RESULTS: A total of 221 patients were included in the analyses - 169 (76.5%) were in the control group and 52 (23.5%) were in the chemo delay group. On multi-variate analysis, risk factors that were significantly associated with a delay in initiation in chemotherapy included: age >65, albumin <3.5, and high age-adjusted Charlson Comorbidity Index score. Delay in chemotherapy initiation was associated with a shorter progression-free (p=0.014) but not overall survival (p=0.19). CONCLUSIONS: Delay in initiation of chemotherapy affected 23.5% of patients in our study population. Easily identifiable risk factors for chemotherapy delay exist that can help us pre-operatively identify patients for which neoadjuvant chemotherapy may be a better treatment option. Further study into prospective modeling with these identified risk factors is warranted.
OBJECTIVE: The objective of this study was to identify preoperative characteristics of patients that experience a delay in initiation of adjuvant chemotherapy after primary debulking surgery for ovarian cancer. MATERIALS/ METHODS: We performed a retrospective review of patients with Stage II to IV high-grade epithelial ovarian, tubal, and peritoneal carcinoma who underwent primary debulking surgery followed by adjuvant chemotherapy from 2005 to 2013. Patients were divided into 2 groups: Control (those who received their first cycle of chemotherapy within 6weeks of debulking surgery) vs. chemotherapy delay (those who received their first cycle of chemotherapy at an interval >6weeks from primary debulking surgery). Relevant clinical variables and survival outcomes were compared between the 2 groups using standard statistical methods. RESULTS: A total of 221 patients were included in the analyses - 169 (76.5%) were in the control group and 52 (23.5%) were in the chemo delay group. On multi-variate analysis, risk factors that were significantly associated with a delay in initiation in chemotherapy included: age >65, albumin <3.5, and high age-adjusted Charlson Comorbidity Index score. Delay in chemotherapy initiation was associated with a shorter progression-free (p=0.014) but not overall survival (p=0.19). CONCLUSIONS: Delay in initiation of chemotherapy affected 23.5% of patients in our study population. Easily identifiable risk factors for chemotherapy delay exist that can help us pre-operatively identify patients for which neoadjuvant chemotherapy may be a better treatment option. Further study into prospective modeling with these identified risk factors is warranted.
Authors: Kelly L Singel; Tiffany R Emmons; Anm Nazmul H Khan; Paul C Mayor; Shichen Shen; Jerry T Wong; Kayla Morrell; Kevin H Eng; Jaron Mark; Richard B Bankert; Junko Matsuzaki; Richard C Koya; Anna M Blom; Kenneth R McLeish; Jun Qu; Sanjay Ram; Kirsten B Moysich; Scott I Abrams; Kunle Odunsi; Emese Zsiros; Brahm H Segal Journal: JCI Insight Date: 2019-03-07
Authors: Ying L Liu; Qin C Zhou; Alexia Iasonos; Olga T Filippova; Dennis S Chi; Oliver Zivanovic; Yukio Sonoda; Ginger Gardner; Vance Broach; Roisin OCearbhaill; Jason A Konner; Carol A Aghajanian; Kara Long; William Tew Journal: Int J Gynecol Cancer Date: 2020-06-09 Impact factor: 4.661
Authors: Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Helena C van Doorn; Heleen J van Beekhuizen Journal: Cancers (Basel) Date: 2022-08-29 Impact factor: 6.575
Authors: Stephanie Stelten; Christelle Schofield; Yvonne A W Hartman; Pedro Lopez; Gemma G Kenter; Robert U Newton; Daniel A Galvão; Meeke Hoedjes; Dennis R Taaffe; Luc R C W van Lonkhuijzen; Carolyn McIntyre; Laurien M Buffart Journal: Cancers (Basel) Date: 2022-09-20 Impact factor: 6.575